BALAXI
Invest Now
Start SIP in
BALAXI
Performance
- Low
- ₹49
- High
- ₹50
- 52 Week Low
- ₹49
- 52 Week High
- ₹129
- Open Price₹50
- Previous Close₹49
- Volume105,648
Investment Returns
- Over 1 Month -2.08%
- Over 3 Month -26.01%
- Over 6 Month -33.1%
- Over 1 Year -55%
Smart Investing Starts Here Start SIP with Balaxi Pharmaceuticals for Steady Growth!
Balaxi Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 10.8
- PEG Ratio
- 0
- Market Cap Cr
- 270
- P/B Ratio
- 1.3
- Average True Range
- 1.71
- EPS
- 4.54
- Dividend Yield
- 0
- MACD Signal
- -0.88
- RSI
- 39
- MFI
- 11.29
Balaxi Pharmaceuticals Financials
Balaxi Pharmaceuticals Technicals
EMA & SMA
Current Price
₹48.91
-0.14
(-0.29%)

-
- Bearish Moving Average 16
-
- Bullish Moving Average 0
- 20 Day
- ₹49.74
- 50 Day
- ₹52.14
- 100 Day
- ₹57.40
- 200 Day
- ₹67.81
Resistance and Support
49.09
- R3 49.97
- R2 49.74
- R1 49.32
- S1 48.67
- S2 48.44
- S3 48.02
Balaxi Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2025-05-30 | Audited Results & Others | To consider other business matters. split from Rs. 10/- to Rs. 2/-. |
2025-02-10 | Quarterly Results & Others | To consider other business matters. split from Rs. 10/- to Rs. 2/-. |
2024-11-05 | Quarterly Results & Others | To consider other business matters. split from Rs. 10/- to Rs. 2/-. |
2024-08-02 | Quarterly Results | |
2024-05-29 | Audited Results |
Balaxi Pharmaceuticals F&O
About Balaxi Pharmaceuticals
- NSE Symbol
- BALAXI
- BSE Symbol
- Managing Director
- Mr. Ashish Maheshwari
- ISIN
- INE618N01022
Similar Stocks to Balaxi Pharmaceuticals
Balaxi Pharmaceuticals FAQs
Balaxi Pharmaceuticals share price is ₹48 As on 18 July, 2025 | 00:23
The Market Cap of Balaxi Pharmaceuticals is ₹270 Cr As on 18 July, 2025 | 00:23
The P/E ratio of Balaxi Pharmaceuticals is 10.8 As on 18 July, 2025 | 00:23
The PB ratio of Balaxi Pharmaceuticals is 1.3 As on 18 July, 2025 | 00:23
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.